...analysis to detect residual disease.Relay buying machine learning company ZebiAIPrecision oncology and genetic diseases company Relay Therapeutics Inc....
...3-kinase mTOR (FRAP) (RAFT1) - Mammalian target of rapamycin BC Staff gedatolisib (PF-05212384, pki-587) Lumicks B.V. Molecular Assemblies Inc. Celcuity Inc. Surrozen Inc. Relay Therapeutics Inc. C2i...

...convergence of data science, machine learning and drug discovery,” said Foresite’s Michael Rome, who cited Relay Therapeutics Inc....

...BRAF and FGFR2/3 mutants in preclinical development. Relay Therapeutics Inc....

...AlphaFold because the structures were there,” said Relay Therapeutics Inc....
...– Interleukin-2 receptor alpha chain Karen Tkach Tuzman Alphabet Inc. Relay Therapeutics Inc. Neoleukin...

...with its $487.3 million offering in June. Relay Therapeutics Inc....

...unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered with Relay Therapeutics Inc....
...Src homology protein tyrosine phosphatase 2 Lauren Martz RLY-1971 Genentech Inc. Relay Therapeutics Inc. KRAS...

...IPOs for cancer companies delivered postmoney valuations in the $1.7 billion range. Precision oncology play Relay Therapeutics Inc....

...fifth of a warrant redeemable at $11.50 The series of offerings came the day after Relay Therapeutics Inc....

...FGF) receptor 2 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Relay Therapeutics Inc. ALX...

...and the price range earlier in the day from a prior proposal. A third biotech, Relay Therapeutics Inc....
...in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta Inc. Relay Therapeutics Inc. Inventiva...